Boehringer Ingelheim International GmbH 뉴스

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelhe

1월 10일 08:38

Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that empagliflozin was associated with a decreas

2019년 11월 18일 10:41

Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whet

2019년 11월 13일 10:00

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing

Boehringer Ingelheim today presented promising preclinical data from its pan-KRAS program including the novel, oral inhibitor BI 1701963 at the AACR-NCI-EORTC International Conference on Molecular Tar

2019년 10월 30일 10:26

Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CF™ 1)

Boehringer Ingelheim today announced the first patient enrolled in its Phase II clinical trial BALANCE-CF™ 1 to evaluate a new potential treatment for cystic fibrosis.[1,2] The trial will investigate

2019년 10월 17일 10:45

New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes

Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olod

2019년 10월 1일 16:37

INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases[1]

Boehringer Ingelheim announced today that in the Phase III INBUILD® trial nintedanib slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline

2019년 9월 30일 15:43

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with

2019년 9월 23일 13:10

Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a post-hoc analysis of the landmark EMPA-REG OUTCOME® trial that were presented at the 55th Annual Meeting of the

2019년 9월 20일 09:05

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for

2019년 9월 4일 17:43

Results from RE-SPECT CVT® published - first trial of NOAC in cerebral venous thrombosis

Boehringer Ingelheim today announced the publication of primary analysis from RE-SPECT CVT®, the first exploratory, prospective, randomised controlled study of a NOAC in patients with blood clots in t

2019년 9월 4일 17:40

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, whi

2019년 9월 3일 17:10

Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication[1-3] recognising the contribution made in the decade since by patients, healthcare professionals (HCPs) an

2019년 8월 30일 17:20

Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types

2019년 8월 13일 09:48

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeut

2019년 7월 16일 13:03

Dabigatran’s safety and efficacy established for management of VTE in children

Boehringer Ingelheim today announced results from two paediatric studies of dabigatran etexilate, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress i

2019년 7월 9일 17:29

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

Boehringer Ingelheim and Yuhan Corporation today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseas

2019년 7월 2일 09:22

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 7650

2019년 6월 18일 10:16

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing protei

2019년 6월 12일 10:19

Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glim

2019년 6월 11일 14:59

New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuria

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a new post-hoc analysis of data from the EMPA-REG OUTCOME® trial. These results indicated that the effect of empag

2019년 6월 11일 10:18

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gubra’s established exp

2019년 5월 29일 18:19

Network of 1,500 Stroke-Ready Clinics across Europe

The Angels Initiative announced today at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals acr

2019년 5월 24일 09:30

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD[1]

Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVCa) in patients with systemic sclerosis assoc

2019년 5월 22일 09:43

Trial results of Pradaxa® vs ASA in ESUS published in NEJM

Boehringer Ingelheim today announced full results from the RE-SPECT ESUS® trial, a Phase III randomised, double-blind study investigating the efficacy and safety of Pradaxa® (dabigatran etexilate) ver

2019년 5월 16일 19:49

Boehringer Ingelheim International GmbH